Oryzon raises €12 million through share placement
- Investing.com
- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Oryzon Genomics SA (ORY)
Track today's live Oryzon Genomics (ORY) share price, performance and key data on this page with our current Madrid:ORY stock exchange information. Analyse interactive charts and historical data, check technical buy and sell signals in real time, and follow the Oryzon Genomics share price on the Madrid exchange. Use the dropdown to switch exchange for the ORY share price, head to our technical summary section, which provides analysis on Oryzon Genomics share price buy/sell indicators using real-time data (or discuss the Oryzon Genomics (ORY) stock price today with other investors in the Oryzon Genomics BME share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current BME:ORY share price (ISIN: ES0167733015) to enhance your trading decisions with our free investment tools and resources.
What Is the Oryzon Genomics SA Share Price Today?
The Oryzon Genomics share price today is 2.880.
What Is the Stock Symbol for Oryzon Genomics SA
The stock symbol (or 'ticker') for Oryzon Genomics SA is "ORY."
What Stock Exchange Does Oryzon Genomics SA Trade On?
Oryzon Genomics SA is listed and trades on the Madrid stock exchange.
Is Oryzon Genomics SA a Good Stock to Buy?
Determining whether Oryzon Genomics (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Use the dropdown to select a relevant stock exchange for the current BME:ORY share price (ISIN: ES0167733015) to enhance your trading decisions with our free investment tools and resources.
What Is the Oryzon Genomics SA Share Price Today?
The Oryzon Genomics share price today is 2.880.
What Is the Stock Symbol for Oryzon Genomics SA
The stock symbol (or 'ticker') for Oryzon Genomics SA is "ORY."
What Stock Exchange Does Oryzon Genomics SA Trade On?
Oryzon Genomics SA is listed and trades on the Madrid stock exchange.
Is Oryzon Genomics SA a Good Stock to Buy?
Determining whether Oryzon Genomics (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
2.880
-0.004(-0.14%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.870
2.968
52 wk Range
2.555
4.020
ORY is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.8702.968
52 wk Range
2.5554.020
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
ORY Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
7.133
Upside
+147.69%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Stock generally trades with low price volatility
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Neutral
Moving Averages
Sell
Analyst Ratings
3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 7.133
(+147.69% Upside)
Earnings
Latest Release
27/07/2026
EPS / Forecast
-- / -0.06
Revenue / Forecast
-- / --
Compare ORY to Peers and Sector
Metrics to compare | ORY | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipORYPeersSector | |
|---|---|---|---|---|
P/E Ratio | −99.9x | 12.4x | −0.3x | |
PEG Ratio | −2.82 | 0.26 | 0.00 | |
Price/Book | - | 2.0x | 2.6x | |
Price / LTM Sales | 21.8x | 3.3x | 3.0x | |
Upside (Analyst Target) | 80.6% | 249.7% | 56.7% | |
Fair Value Upside | Unlock | 15.1% | 9.4% | Unlock |
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS (central nervous system), oncology, and hematology disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases; and ORY-4001, a selective HDAC-6 inhibitor for the treatment of neurological disorders, such as Charcot-Marie-Tooth disease (CMT), amyotrophic lateral sclerosis (ALS), and others. It also has collaborations in precision medicine with Columbia University in New York and the Institute of Medical and Molecular Genetics (INGEMM) at La Paz Hospital in Madrid psychometrically characterize patients with mutations in the SetD1A or Shank3 genes; and Cooperative Research and Development Agreement (CRADA) to sponsor several clinical trials. The company was incorporated in 2000 and is based in Cornellà de Llobregat, Spain.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Oryzon Genomics (Madrid: ORY) Share Price Today?
The Oryzon Genomics stock price today is 2.880 EUR.
What Stock Exchange Does Oryzon Genomics (ORY) Trade On?
Oryzon Genomics is listed and trades on the Madrid Stock Exchange.
What Is the Ticker (Stock Symbol) for Oryzon Genomics?
The stock symbol (also called a 'ticker') for Oryzon Genomics is "ORY."
What Is the Current Oryzon Genomics Market Capitalisation?
As of today, Oryzon Genomics (Madrid: ORY) market cap is 236.040M EUR.
What Is Oryzon Genomics's (ORY) Earnings Per Share (TTM)?
The Oryzon Genomics EPS is currently -0.035 (Trailing Twelve Months).
When Is the Next Oryzon Genomics Earnings Date?
Oryzon Genomics's next earnings report will be released on 22/10/2026.
Is ORY a Buy or Sell From a Technical Analyst Perspective?
Based on today's Oryzon Genomics moving averages and other technical indicators, the daily buy/sell signal for ORY stock is Strong Sell.
How Many Times Has Oryzon Genomics Stock Split?
Oryzon Genomics has split 0 times. (See the ORY stock split history page for full effective split date and price information.)
How Many Employees Does Oryzon Genomics Have?
Oryzon Genomics has 46 employees, based on their latest Companies House report.
What is the current trading status of Oryzon Genomics (Madrid: ORY)?
As of 01/08/2026, Oryzon Genomics (ORY) is trading at a share price of 2.880 EUR, with a previous close of 2.884 EUR. The stock has fluctuated within a day range of 2.870 EUR to 2.968 EUR, while its 52-week range spans from 2.555 EUR to 4.020 EUR.
What Is Oryzon Genomics (ORY) Price Target According to Analysts?
The average 12-month price target for Oryzon Genomics is 7.133 EUR, with a high estimate of 12 EUR and a low estimate of 4.2 EUR. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +147.69% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.